News

Researchers were able to rule out myocardial infarction in 30% of patients immediately, and another 25% of patients at 1 hour. By 3 hours, the assay had successfully ruled out MI in 83.8% of patients, versus the 80.4% ruled out under the conventional assay.

Two studies examine whether users of daily oral PrEP would switch to a long-acting injection with interesting results.

Meeting with a peer support worker to complete a personal recovery workbook reduced readmissions over a year for patients with mental health challenges.

How researchers are using stem cells and a greater patient population to improve on the invasive methods used to treat the common women's disease.

Stay up-to-date on the latest rare disease news by reading the top 5 articles of the week.

Merck’s new non-nucleoside reverse transcriptase inhibitor (NNRTI), doravirine, achieved viral suppression in 73.1% of patients, according to new data released by the company.

The DR market is expected to accrue a sum of $2,490 million by 2022, growing at a compound annual growth rate of 14.4% from 2014-2022.

Financial hardship in a substantial proportion of adult survivors of childhood cancer was found by investigators from St Jude Children’s Research Hospital, suggesting screening for financial problems in patients.

The New England Journal of Medicine has published the 48-week phase 3 clinical trial results that supported the FDA approval of L-glutamine oral powder for the reduction of acute complications of sickle cell disease in adult and pediatric patients.

A phase 3 trial to investigate lenabasum as a potential treatment for dermatomyositis, a rare and often fatal multisystem inflammatory autoimmune disease affecting muscle and skin, have been announced by Corbus Pharmaceuticals Holdings, Inc.

New research finds that the prevalence of opioid use remained high during the study period from 2007 to 2016.

The FDA has granted an orphan drug designation to ArmaGen Inc.’s GT-184 for the treatment of mucopolysaccharidosis type IIIA.

Investigators from Milan, Italy, have identified an important molecule involved in the onset of systemic scleroderma.

Times are tough. Medicine needs a hero.

The FDA has granted a breakthrough therapy designation to Daiichi Sankyo Company, Limited’s investigational FLT3 inhibitor, quizartinib, for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML).

Research suggests that elevated glycemia, low blood pressure, and low BMI may be identifying markers for dementia risk and possible targets for management or prevention.

The combined results of a recent meta-analysis and a new population-based study supports there being a significant association between asthma and ADHD.

Phase 3 trial assessing RHB-104 as a treatment for Crohn’s disease yields positive results.

High levels of the protein Mfn2 were found to prevent nerve degeneration, muscle atrophy, and paralysis of amyloid lateral sclerosis (ALS) in a mouse model.

Researchers investigate whether the location of a mutation in the PIK3CA gene affects the mutation’s ability to drive cancerous growth.

After a high-volume flu season driven by outbreak of the mutated H3N2 strain, Sanofi has bolstered its vaccine class with options specific to older populations.

Clinical trials consistently demonstrate that fecal microbiota treatment is an effective treatment strategy for recurrent CDI, yet standardization practices vary.

The second member of the FDA-approved thrombopoietin receptor agonist drug class was proven efficacious and safe in a pair of phase 3 trials.

Leading artificial intelligence companies have partnered up to develop new drug candidates for Duchenne muscular dystrophy.

The 2 assays from Ortho Clinical Diagnosis consolidates the company's package of devices and systems designed to give patients frequent diagnoses.

In a new study, researchers say they’ve improved on a method of delivering probiotics to premature newborns in the fight against deadly gut infections.

The optimal duration of dual antiplatelet therapy remains unclear, despite being proven efficacious for roughly 2 decades.

The FDA granted an orphan designation to Surface Oncology’s SRF231 for the treatment of multiple myeloma, a rare blood cancer.